Breast Center, Kameda Medical Center, Kamogawa, Japan.
Jpn J Radiol. 2010 Feb;28(2):101-9. doi: 10.1007/s11604-009-0391-7. Epub 2010 Feb 26.
The aim of this study was to assess the efficacy of single-voxel (1)H magnetic resonance spectroscopy (MRS) at 1.5 T to evaluate early responses to neoadjuvant chemotherapy after the first treatment in breast cancer patients and to compare it to measurements of apparent diffusion coefficient (ADC) values derived from diffusion-weighted magnetic resonance imaging (MRI).
Nine patients with breast cancer who were scheduled to receive neoadjuvant chemotherapy were recruited. MR examination after the first cycle was scheduled for a few days before the administration of the second dose.
Two patients were excluded from the study because their regimen was changed after the first cycle. MRS before chemotherapy demonstrated the presence of choline (Cho) at 3.22-3.23 ppm in six cases and at 3.27 ppm in one case. Diffusion-weighted MRI before chemotherapy demonstrated a localized high-signal lesion in all cases. The change of the integral value of Cho after the first cycle of chemotherapy showed a positive correlation with the change in lesion size (r = 0.91, P = 0.01), whereas no correlation was observed between the change of ADC values after the first cycle and the change in lesion size (r = 0.45, P = 0.32).
MRS after the first cycle may be more sensitive to diffusion-weighted MRI to predict the pathological response.
本研究旨在评估 1.5T 单体素(1)H 磁共振波谱(MRS)在评估乳腺癌患者新辅助化疗第一周期后早期疗效方面的作用,并将其与从磁共振弥散加权成像(MRI)获得的表观弥散系数(ADC)值的测量进行比较。
招募了 9 名计划接受新辅助化疗的乳腺癌患者。在给予第二剂量之前的几天内安排进行第一次周期后的 MR 检查。
由于第一周期后方案改变,两名患者被排除在研究之外。化疗前 MRS 显示在 6 例中在 3.22-3.23ppm 处存在胆碱(Cho),在 1 例中在 3.27ppm 处存在 Cho。化疗前弥散加权 MRI 显示所有病例均存在局灶性高信号病变。第一周期化疗后 Cho 积分值的变化与病变大小的变化呈正相关(r = 0.91,P = 0.01),而第一周期后 ADC 值的变化与病变大小的变化之间无相关性(r = 0.45,P = 0.32)。
第一周期后的 MRS 可能比弥散加权 MRI 更敏感,可预测病理反应。